newsfilter
← Latest News
Business Wire·

Gossamer Bio Announces First Quarter 2026 Financial Results and Provides Business Update

- FDA Confirms In-Person Pre-NDA Type B Meeting in Mid-June - - Positive PROSERA CT FRI Results Demonstrated Multiple Statistically Significant Treatment Effects, Including Novel Signals Correlated with Clinical